Dr Maria Fernanda Arboleda is an Anesthesiologist, Pain and Palliative Care Physician. She also completed a Spine-Regional Anesthesia Fellowship at the McGill University Health Center and most recently, she completed a Postdoctoral Research Fellow in Supportive Cancer Care and Medical Cannabis, at the Department of Oncology, McGill University, and at Sante Cannabis, a leading specialized cannabis clinic in Canada.
Presently, Dr Arboleda is the Medical Director of Khiron Life Sciences Corp. Likewise, she is a co-investigator on several research projects that are being developed in Canada, including the deployment of a phase ll study on the use of cannabis oil capsules for chronic pain, as well as the first phase lll study for the use of inhaled cannabis to improve health-related quality of life in advanced cancer patients.
Despite the growing popularity of medical cannabis oil consumption for a diverse control, the is still incomplete data concerning the pharmacokinetics, safety and efficiency. For this reason, we deployed a first in-human Phase 1 trial to assess the safety and pharmacological characteristics of a pharmaceutical-grade cannabis oil capsule. PPP005 containing 10 mg delta-9-tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD), orally administered to healthy male and female subjects. The design and characteristics of the study, outcome measurements, pharmacokinetic and safety data, as well as future directions, will all be exposed throughout the poster presentation.